| 產(chǎn)品編號 | BIO1004SM |
| 英文名稱 | Anti-HER2/neu & HER3 Reference Antibody (Zenocutuzumab Biosimilar) |
| 別 名 | ERBB2 / HER2 / CD340 & ERBB3 / HER3; Zenocutuzumab |
| 抗體來源 | |
| 克隆類型 | Monoclonal |
| 交叉反應(yīng) | Human |
| 產(chǎn)品應(yīng)用 |
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 145.88kDa |
| 性 狀 | Lyophilized |
| 亞 型 | IgG-like |
| 純化方法 | Protein A |
| 緩 沖 液 | 100 mM Pro-Ac 20mM Arg pH 5.0 |
| 保存條件 | -80°C for 2 years under sterile conditions； -20°C for 1 year under sterile conditions；Avoid repeated freeze-thaw cycles. |
| 注意事項(xiàng) | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 | |
| 產(chǎn)品圖片 |
Co-incubation of Zenocutuzumab with BT474 cell and PBMCs for 4 hours, then LDH was detected to evaluate the ADCC activity of Zenocutuzumab. As shown in fig, Zenocutuzumab has ADCC activity, and the IC50 was 0.031 nM.
Zenocutuzumab bound to Hu-HER3-FL-HEK293 cells, and then rebounded to fluorescent secondary antibodies(Anti-Human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Zenocutuzumab bound to Hu-HER3-FL-HEK293 cells, and the EC50 was 0.879 nM.
Zenocutuzumab bound to BT474 cells, and then rebounded to fluorescent secondary antibodies(Anti-human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Zenocutuzumab bound to BT474 cells, and the EC50 was 1.277 nM.
Zenocutuzumab bound to HER2 protein, and then rebounded to secondary antibodies(Anti-human-IgG-Fc-HRP) , and read OD450. As shown in fig, Zenocutuzumab bound to hu-HER2-his, and the EC50 was 0.017 nM.
The purity of Anti-HER2/neu & HER3 Reference Antibody (Zenocutuzumab) is 100.00%, determined by SEC-HPLC.
Anti-HER2/neu & HER3 Reference Antibody (Zenocutuzumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
The detected molecular weight of Anti-HER2 & HER3 Reference Antibody (Zenocutuzumab) is 145.20 kDa.
|
